European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has been approved by the European Commission (EC). The ...

“Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” said Governor Maura Healey, in a statement. “We are thrilled to see them ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and then, ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...